Infections due to Acinetobacter Baumannii in the ICU

Jean Chastre

doi:10.1055/s-2003-37918

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2003; 24(1): 069-078
DOI: 10.1055/s-2003-37918

Infections due to Acinetobacter Baumannii in the ICU

Jean Chastre

Service de Réanimation Médicale, Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

Abstract

ABSTRACT

Acinetobacter species are widespread environmental, nonfermentative, aerobic, gram-negative coccobacilli. Most infections due to this organism are opportunistic in nature and occur in patients who spend extended time in the intensive care unit (ICU) due to severe underlying disease, and who need prolonged therapy with mechanical ventilation and antimicrobial agents. Because the only factor amenable to prevention in this setting is antimicrobial therapy, avoidance of unnecessary antibiotics should be a high priority in management of such patients. Nosocomial spread of A. baumannii in the ICU setting has often been attributed to ventilatory equipment and to colonized nursing and respiratory personnel via hand transmission. In fact, the epidemiology of nosocomial respiratory colonization and/or infection with A. baumannii is now commonly much more complex due to the coexistence of epidemic cases with unrelated sporadic cases caused by different strains. This underscores the necessity to use molecular typing to improve the detection of microepidemics amenable to early control. Crude mortality rates of 30 to 75% have been reported for nosocomial infection due to Acinetobacter species, with the highest rates reported in ventilator-dependent patients. As with many other opportunistic gram-negative bacilli, increasing antibiotic resistance has hindered the therapeutic management of nosocomial infection due to Acinetobacter species. A. baumannii are now frequently resistant to most available antibacterial drugs, with some centers reporting up to 80% of strains resistant to all aminoglycosides. Even resistance to imipenem, which was for several years the most effective drug in treating Acinetobacter nosocomial infections, has now been described in several reports. Unfortunately, the unique propensity of Acinetobacter species to develop resistance to multiple antimicrobial agents reinforces concerns about the imminence of a post-antimicrobial era where no effective antibiotics will be available to treat this type of infection.

KEYWORDS

Acinetobacter baumannii, nonfermenters - antimicrobial resistance - nosocomial infections

Full Text

References

REFERENCES

1 Struelens M J, Carlier E, Maes N, Serruys E, Quint W G, van Belkum A. Nosocomial colonization and infection with multiresistant Acinetobacter baumannii: outbreak delineation using DNA macrorestriction analysis and PCR-fingerprinting. J Hosp Infect . 1993; 25 15-32
2 Villers D, Espaze E, Coste-Burel M. Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology. Ann Intern Med . 1998; 129 182-189
3 Go E S, Urban C, Burns J. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet . 1994; 344 1329-1332
4 Bergogne-Berezin E. The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents. J Hosp Infect . 1995; 30 (suppl 4) S441-S445
5 Richards M J, Edwards J R, Culver D H, Gaynes R P. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med . 1999; 27 887-892
6 National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control . 1999; 27 520-532
7 Chastre J, Fagon J Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med . 2002; 165 867-903
8 Chastre J, Fagon J Y, Lamer C. Procedures for the diagnosis of pneumonia in ICU patients. Intensive Care Med . 1992; 18 (suppl 1) S10-S17
9 Fagon J Y, Chastre J, Hance A J, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med . 1993; 94 281-288
10 Fagon J Y, Chastre J, Domart Y. Nosocomial pneumonia in patients receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis . 1989; 139 877-884
11 Torres A, Aznar R, Gatell J M. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis . 1990; 142 523-528
12 Rello J, Sa-Borges M, Correa H, Leal S R, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med . 1999; 160 608-613
13 Trouillet J L, Chastre J, Vuagnat A. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med . 1998; 157 531-539
14 Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: a consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med . 1996; 153 1711-1725
15 Cook D J, Walter S D, Cook R J. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med . 1998; 129 433-440
16 Craven D E, Steger K A. Nosocomial pneumonia in mechanically ventilated adult patients: epidemiology and prevention in 1996. Semin Respir Infect . 1996; 11 32-53
17 Baraibar J, Correa H, Mariscal D, Gallego M, Valles J, Rello J. Risk factors for infection by Acinetobacter baumannii in intubated patients with nosocomial pneumonia. Chest . 1997; 112 1050-1054
18 Gomez J, Simarro E, Banos V. Six-year prospective study of risk and prognostic factors in patients with nosocomial sepsis caused by Acinetobacter baumannii Eur J Clin Microbiol Infect Dis . 1999; 18 358-361
19 Peacock Jr E J, Sorrell L, Sottile F D, Price L E, Rutala W A. Nosocomial respiratory tract colonization and infection with aminoglycoside-resistant Acinetobacter calcoaceticus var. anitratus: epidemiologic characteristics and clinical significance. Infect Control Hosp Epidemiol . 1988; 9 302-308
20 Lortholary O, Fagon J Y, Hoi A B. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis . 1995; 20 790-796
21 Rello J, Ausina V, Ricart M, Castella J, Prats G. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest . 1993; 104 1230-1235
22 Husni R N, Goldstein L S, Arroliga A C. Risk factors for an outbreak of multidrug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest . 1999; 115 1378-1382
23 Garcia-Garmendia J L, Ortiz-Leyba C, Garnacho-Montero J. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis . 2001; 33 939-946
24 Simor A E, Lee M, Vearncombe M. An outbreak due to multiresistant Acinetobacter baumannii in a burn unit: risk factors for acquisition and management. Infect Control Hosp Epidemiol . 2002; 23 261-267
25 Buxton A E, Anderson R L, Werdegar D, Atlas E. Nosocomial respiratory tract infection and colonization with Acinetobacter calcoaceticus: epidemiologic characteristics. Am J Med . 1978; 65 507-513
26 Vandenbroucke-Grauls C M, Kerver A J, Rommes J H, Jansen R, den Dekker C, Verhoef J. Endemic Acinetobacter anitratus in a surgical intensive care unit: mechanical ventilators as reservoir. Eur J Clin Microbiol Infect Dis . 1988; 7 485-489
27 Hartstein A I, Rashad A L, Liebler J M. Multiple intensive care unit outbreak of Acinetobacter calcoaceticus subspecies anitratus respiratory infection and colonization associated with contaminated, reusable ventilator circuits and resuscitation bags. Am J Med . 1988; 85 624-631
28 Hartstein A I, Morthland V H, Rourke Jr W J. Plasmid DNA fingerprinting of Acinetobacter calcoaceticus subspecies anitratus from intubated and mechanically ventilated patients. Infect Control Hosp Epidemiol . 1990; 11 531-538
29 Biendo M, Laurans G, Lefebvre J F, Daoudi F, Eb F. Epidemiological study of an Acinetobacter baumannii outbreak by using a combination of antibiotyping and ribotyping. J Clin Microbiol . 1999; 37 2170-2175
30 Wisplinghoff H, Perbix W, Seifert H. Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis . 1999; 28 59-66
31 Landman D, Quale J M, Mayorga D. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med . 2002; 162 1515-1520
32 Wu T L, Su L H, Leu H S. Molecular epidemiology of nosocomial infection associated with multi-resistant Acinetobacter baumannii by infrequent-restriction-site PCR. J Hosp Infect . 2002; 51 27-32
33 Bergogne-Berezin E, Joly-Guillou M L. Hospital infection with Acinetobacter spp.: an increasing problem. J Hosp Infect . 1991; 18 (suppl A) 250-255
34 The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol . 2002; 23 106-108
35 Garcia-Garmendia J L, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez F J, Monterrubio-Villar J, Gili-Miner M. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med . 1999; 27 1794-1799
36 Brown R B, Kruse J A, Counts G W, Russell J A, Christou N V, Sands M L. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group. Antimicrob Agents Chemother . 1990; 34 269-272
37 Goldstein I, Wallet F, Robert J, Becquemin M H, Marquette C H, Rouby J J. Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med . 2002; 165 171-175
38 Elman M, Goldstein I, Marquette C H, Wallet F, Lenaour G, Rouby J J. Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology . 2002; 97 199-206
39 Fridkin S K, Steward C D, Edwards J R. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis . 1999; 29 245-252
40 Hanberger H, Garcia-Rodriguez J A, Gobernado M, Goossens H, Nilsson L E, Struelens M J. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in five European countries. French and Portuguese ICU Study Groups. JAMA . 1999; 281 67-71
41 Mahgoub S, Ahmed J, Glatt A E. Completely resistant Acinetobacter baumannii strains. Infect Control Hosp Epidemiol . 2002; 23 477-479
42 Henwood C J, Gatward T, Warner M. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother . 2002; 49 479-487
43 Koprnova J, Svetlansky I, Babel'a R. Prospective study of antibacterial susceptibility, risk factors and outcome of 157 episodes of Acinetobacter baumannii bacteremia in 1999 in Slovakia. Scand J Infect Dis . 2001; 33 891-895
44 Levin A S, Barone A A, Penco J. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii Clin Infect Dis . 1999; 28 1008-1011
45 Montero A, Ariza J, Corbella X. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii Antimicrob Agents Chemother . 2002; 46 1946-1952
46 Wolff M, Joly-Guillou M L, Farinotti R, Carbon C. In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother . 1999; 43 1406-1411
47 Corbella X, Ariza J, Ardanuy C. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii J Antimicrob Chemother . 1998; 42 793-802
48 Saugar J M, Alarcon T, Lopez-Hernandez S, Lopez-Brea M, Andreu D, Rivas L. Activities of polymyxin B and cecropin A-,melittin peptide CA(1-8)M(1-18) against a multiresistant strain of Acinetobacter baumannii Antimicrob Agents Chemother . 2002; 46 875-878
49 Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med . 1996; 22 387-394
50 Kollef M H, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest . 1998; 113 412-420
51 Rello J, Gallego M, Mariscal D, Sonora R, Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med . 1997; 156 196-200